Thomas A. Abrams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas A. Abrams has a total of 309 co-authors. Here are the top co-authors by number of shared publications:
- Douglas A. Rubinson
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
90 shared publications - Kimberly Perez
Dana-Farber Cancer Institute, Boston, MA
85 shared publications - Benjamin L. Schlechter
Dana-Farber Cancer Institute 1 , Boston, Massachusetts
83 shared publications - Brian M. Wolpin
Dana-Farber Cancer Institute, Boston, MA
82 shared publications - James M. Cleary
Dana-Farber Cancer Institute 1 Boston, MA
69 shared publications - Harshabad Singh
Dana-Farber Cancer Institute, Boston, MA
68 shared publications
Latest Publications
- 21 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF18
Impact of Vitamin D on the Colon Cancer Immune Microenvironment: Results of a Randomized Clinical Trial of Preoperative Vitamin D Supplementation in Patients with Stage I–III Colon Cancer
Although vitamin D (VitD) exhibits antitumor activity in colorectal cancer preclinically, its effects in the human tumor microenvironment (TME) remain unclear. We conducted a randomized, placebo-controlled trial of preoperative high-dose VitD supplementation in patients with stage I to III colon cancer to assess its impact on the TME. Forty-two patients received either VitD3 (50,000 IU/day for 7 days, then 10,000 IU/day) or placebo before surgery. Spatial immune profiling and assessment of VitD receptor (VDR) and CYP27B1 expression were performed on paired tumor samples from 24 patients. VitD significantly increased plasma 25-hydroxyvitamin D levels (P < 0.001), increased CD3+CD8+ memory T cells (P = 0.03), reduced CD3+CD4+FoxP3+ regulatory T cells (P = 0.02), and spatially re-organized the TME, leading to greater T-cell and tumor cell proximity. Posttreatment VDR expression was heterogeneous and decreased overall (P = 0.02). Spatial transcriptomic profiling of posttreatment resections reflected predominantly repressive VDR activity. These findings support an immunomodulatory role for VitD, warranting further mechanistic investigation. Significance: Colorectal cancer remains a leading cause of cancer-related death with limited long-term survival. We evaluated the effects of short-term, preoperative high-dose VitD supplementation on the colon cancer microenvironment in a randomized, placebo-controlled trial. Our findings support VitD as an immune modulator and may inform future treatment strategies.
- 21 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF18
Impact of Vitamin D on the Colon Cancer Immune Microenvironment: Results of a Randomized Clinical Trial of Preoperative Vitamin D Supplementation in Patients with Stage I–III Colon Cancer
Although vitamin D (VitD) exhibits antitumor activity in colorectal cancer preclinically, its effects in the human tumor microenvironment (TME) remain unclear. We conducted a randomized, placebo-controlled trial of preoperative high-dose VitD supplementation in patients with stage I to III colon cancer to assess its impact on the TME. Forty-two patients received either VitD3 (50,000 IU/day for 7 days, then 10,000 IU/day) or placebo before surgery. Spatial immune profiling and assessment of VitD receptor (VDR) and CYP27B1 expression were performed on paired tumor samples from 24 patients. VitD significantly increased plasma 25-hydroxyvitamin D levels (P < 0.001), increased CD3+CD8+ memory T cells (P = 0.03), reduced CD3+CD4+FoxP3+ regulatory T cells (P = 0.02), and spatially re-organized the TME, leading to greater T-cell and tumor cell proximity. Posttreatment VDR expression was heterogeneous and decreased overall (P = 0.02). Spatial transcriptomic profiling of posttreatment resections reflected predominantly repressive VDR activity. These findings support an immunomodulatory role for VitD, warranting further mechanistic investigation. Significance: Colorectal cancer remains a leading cause of cancer-related death with limited long-term survival. We evaluated the effects of short-term, preoperative high-dose VitD supplementation on the colon cancer microenvironment in a randomized, placebo-controlled trial. Our findings support VitD as an immune modulator and may inform future treatment strategies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
Supplementary Figure S2 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
Supplementary Figure S2 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 3: Presence of canakinumab does not interfere with the ability to detect IL-1b in patient serum. Baseline serum from three randomly selected patients with pancreatic ductal adenocarcinoma was evaluated by cytokine bead array for IL-1b. For each patient sample, canakinumab was spiked in at the indicated concentrations. Note that measured IL-1b values were consistent across all samples from the same patient, regardless of the presence of canakinumab.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 3: Presence of canakinumab does not interfere with the ability to detect IL-1b in patient serum. Baseline serum from three randomly selected patients with pancreatic ductal adenocarcinoma was evaluated by cytokine bead array for IL-1b. For each patient sample, canakinumab was spiked in at the indicated concentrations. Note that measured IL-1b values were consistent across all samples from the same patient, regardless of the presence of canakinumab.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
Representativeness of Study Participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
Representativeness of Study Participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
Sample Preparation for CyTOF and Olink
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
Sample Preparation for CyTOF and Olink